Compare OPTT & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPTT | CLGN |
|---|---|---|
| Founded | 1984 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Industrial Specialties |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.2M |
| IPO Year | 2006 | 2015 |
| Metric | OPTT | CLGN |
|---|---|---|
| Price | $0.69 | $3.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $45.00 | N/A |
| AVG Volume (30 Days) | ★ 679.5K | 67.3K |
| Earning Date | 09-14-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,737,000.00 | N/A |
| Revenue This Year | $286.98 | N/A |
| Revenue Next Year | $131.02 | $25.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.10 | $0.26 |
| 52 Week High | $3.23 | $4.78 |
| Indicator | OPTT | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 55.96 |
| Support Level | $0.29 | $0.34 |
| Resistance Level | $3.23 | $3.91 |
| Average True Range (ATR) | 0.19 | 0.40 |
| MACD | -0.12 | -0.09 |
| Stochastic Oscillator | 3.19 | 40.83 |
Ocean Power Technologies Inc is specializing in intelligent maritime solutions. These solutions include a variety of as a service systems, including Data as a Service (DaaS), Robotics as a Service (RaaS), and Power as a Service (PaaS). It design, manufacture, deploy, and operate these systems for defense, security, subsea infrastructure, offshore oil and gas, offshore energy, marine research, and communication markets. The company operates as one operating segment. Majority of revenue comes from Europe followed by North & South America; and followed by Asia and Australia.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.